Hims & Hers: CEO Dudum Aims to Gain Market Share During the Crisis
Reading Time: 3 minutes
Despite FDA setback and stock plunge, Hims is focusing on expansion rather than retreat – with a clear strategy beyond GLP-1. From niche player to health platform: New therapy offerings, lab diagnostics, and AI make Hims crisis-resistant and scalable. While geopolitical tensions – fueled by new tariffs from the U.S. and retaliatory measures from China – put pressure on the markets, one company remains remarkably calm: Hims & Hers Health. For CEO Andrew Dudum, times of economic uncertainty are not a phase of retreat but rather...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
